Loading viewer...
earnings
Format: PDF earnings
J.P. Morgan equity research alert on OPKO's phase 3 study of hGH-CTP in adults with growth hormone deficiency, which failed to meet its primary endpoint on trunk fat mass reduction. Despite the disappointing adult results, the company initiated its pediatric phase 3 study, which represents approximately 75% of the total market opportunity.
investor_presentation
27 Pages
OPKO Health Investor Presentation — September 2017
investor_presentationinvestor_presentation
23 Pages
earnings
20 Pages
NorthStar Realty Europe Corporation
Teck Resources Q4 2016 Results Earnings
earningsearnings
19 Pages
Teck Resources Limited
Vienna Insurance Group VIG 2018 Half-Year Results
earningsearnings
51 Pages
Vienna Insurance Group
Ahlstrom 2023 Half Year Financial Results Earnings Call
earningsearnings
17 Pages
Ahlstrom Holding 3 Oy
AEP Q3 2025 Earnings Report & $72B Capital Plan
earningsearnings
10 Pages
American Electric Power